| |
|
|
|
Nymox Pharmaceutical Corporation  
|
|
1.62 0.09 (0.06%) |
06-14 16:00 |
|
Open: |
1.56 |
Pre close: |
1.53 |
Target:
|
2.15 
|
|
High: |
1.65 |
Low: |
1.54 |
Resistance:
|
1.84
2.15
|
|
Volume: |
81,577 |
Market Cap: |
110M |
Support:
|
1.52
1.32
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
1.50
|
MACD |
MACD(12,26):
|
-0.07 |
|
MA(20): |
1.59  |
Signal(12,26,9): |
-0.07 |
|
MA(100): |
1.97 |
Stochastic Oscillator |
%K(14,3):
|
33.33 |
|
MA(250): |
2.23 |
%D(3): |
21.87 |
|
Average Volume(K) |
3-Month: |
8723
|
52-Week |
High:
|
3.90 |
|
10-Days: |
10061 |
Low: |
1.25 |
|
RSI |
RSI(14):
|
50.22 |
Change(%): |
-52.4 |
|
Financials, Statistics and Valuation |
|
EPS |
0.000 |
Return on Equity (ttm) |
-236.4 |
Shares Out. (M) |
67.93 |
|
EPS Est. Current Year |
-0.200 |
Return on Assets (ttm) |
-170.5 |
Shares Float (M) |
41.11 |
|
EPS Est. Next Year |
-0.570 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.00 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
-80.3 |
% Held by Institutions |
11.00 |
|
Forward EPS |
1.#IO |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
0 |
|
Book Value (p.s.) |
9.900 |
EBITDA (p.s.) |
0.000 |
P/E |
0.00 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.16 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-7.56 |
P/S |
0.00 |
|
Operating Margin |
-6161.58 |
Levered Free Cash Flow
(M) |
-3.90 |
P/CF |
-14.56 |
|
|
|
|
|
|
